evitria AG, a global antibody expression service provider located in Zurich, Switzerland, has entered into a non-exclusive bYlok® bispecific pairing technology license agreement with Lonza. Lonza’s bYlok® bispecific pairing technology redefines IgG-like bispecific antibody design with simplicity and confidence to drive correct heavy-light chain (HC-LC) pairing.

evitria is both proud and grateful to be a frequently chosen research partner. Find out how we express our gratitude when being cited in your publication!

As of May 2023, Dr. Stefan Schmidt will take over the position of CEO at evitria. Read more about Dr. Schmidt and his vision for the company in this article.

Das Team von evitria blickt auf Meilensteine und Errungenschaften zurück und setzt das Wachstum des Unternehmens auch 2023 fort.

With more than 20,000 abs and proteins purified, evitria has reached a huge milestone. Read more about its significance and our plans for the future.

Genovis AB and evitria AG signed a service agreement to offer evitria’s customers fast LC-MS characterization of recombinant antibodies using Genovis proprietary enzyme technologies. evitria AG is a world leading service provider for recombinant antibody expression in CHO cells, with headquarters in Zürich, Switzerland.

evitria AG, a Zurich, Switzerland-based contract research, development, and manufacturing organization focused on transient recombinant antibody and protein production, announced that former Director of Client Relations, Richard Park, has been appointed Global Head of Client Relations and Business Development.